Azora Therapeutics, Inc. (DE)
AZR · XNASCIK 1513525fmd_0K4C7Q9NG1QYRVNTXAWM1YY557Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | 0 | 0 | 4 | 6 | 8 | 2 | 1 | 3 | 3 |
| Total operating expenses | 1 | 7 | 8 | 11 | 19 | 11 | 7 | 8 | 8 |
| Operating income | (1) | (7) | (8) | (11) | (19) | (11) | (7) | (8) | (8) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | (5) | (0) | 0 | (0) | 0 | (0) | (5) | (0) |
| Income before taxes | (1) | (12) | (9) | (11) | (20) | (11) | (7) | (13) | (8) |
| Income tax expense | – | – | – | – | (0) | (0) | – | – | – |
| Net income from continuing operations | – | – | – | – | (19) | (11) | (7) | (13) | – |
| Net income | (1) | (12) | (9) | (11) | (19) | (13) | (5) | (13) | (8) |